Lite Strategy LITS
NASDAQ LITS
$1.06 +0.00 (+0.00%)
At close: Sep 10, 2026 · 4:00 PM EDT

Lite Strategy (LITS) Other Non-Current Liabilities (2011 - 2026)

Lite Strategy (LITS) posted Other Non-Current Liabilities of $2.0 million for Q1 2026, little changed on a QoQ basis from $2.0 million in Q4 2025, and down 59.18% year-over-year from $4.9 million in Q1 2025.

Analysis

Lite Strategy (LITS) Other Non-Current Liabilities (2011 - 2026) Analysis & Trends

Lite Strategy has reported Other Non-Current Liabilities for 10 years, with the latest figure at $2.0 million in Q1 2026.

  • On a quarterly basis, Other Non-Current Liabilities fell 59.18% year-over-year to $2.0 million in Q1 2026; TTM through Mar 2026 was $2.0 million, a 59.18% decrease from a year earlier, with the FY2022 full-year figure at $1.6 million, down 92.84% from the prior year.
  • Other Non-Current Liabilities was $2.0 million for Q1 2026 at Lite Strategy, roughly flat from $2.0 million in the prior quarter.
  • The five-year high for Other Non-Current Liabilities was $4.9 million in Q3 2023, with the low at $500000.0 in Q3 2022.
  • Average Other Non-Current Liabilities over 5 years is $3.3 million, with a median of $3.4 million recorded in 2023.
  • The sharpest annual moves came in 2022 and 2023: Other Non-Current Liabilities tumbled 97.47% in 2022, then surged 880.0% in 2023.
  • Over 5 years, Other Non-Current Liabilities stood at $500000.0 in 2022, then soared by 880.0% to $4.9 million in 2023, then changed by 0.0% to $4.9 million in 2024, then sank by 59.18% to $2.0 million in 2025, then changed by 0.0% to $2.0 million in 2026.
  • The last three Other Non-Current Liabilities figures came in at $2.0 million (Q1 2026), $2.0 million (Q4 2025), and $2.0 million (Q3 2025), per Business Quant data.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Amgen 206.44 Bn 192.45 Bn 7.24 Bn
2 Gilead Sciences 179.97 Bn 176.79 Bn 6.22 Bn
3 Vertex Pharmaceuticals 130.57 Bn 122.72 Bn 2.84 Bn
4 Regeneron Pharmaceuticals 81.63 Bn 73.63 Bn 3.93 Bn
5 Argenx Se 60.34 Bn 55.16 Bn 1.37 Bn
6 Moderna 54.37 Bn 49.23 Bn 52.00 Mn
7 Alnylam Pharmaceuticals 33.07 Bn 29.76 Bn 992.69 Mn
8 Biogen 31.84 Bn 30.55 Bn 1.96 Bn
9 Roivant Sciences 29.49 Bn 29.49 Bn 1.16 Mn
10 Lite Strategy 38.03 Mn 30.49 Mn -
Historic Data

Historic Data

Download Data
DateValue
Mar 31, 2026 2.00 Mn
Dec 31, 2025 2.00 Mn
Sep 30, 2025 2.00 Mn
Mar 31, 2025 4.90 Mn
Dec 31, 2024 4.90 Mn
Sep 30, 2024 4.90 Mn
Mar 31, 2024 4.90 Mn
Dec 31, 2023 4.90 Mn
Sep 30, 2023 4.90 Mn
Sep 30, 2022 500,000.00
Jun 30, 2022 1.60 Mn
Mar 31, 2022 1.54 Mn
Dec 31, 2021 14.31 Mn
Sep 30, 2021 19.80 Mn
Jun 30, 2021 22.40 Mn
Mar 31, 2021 29.44 Mn
Dec 31, 2020 20.18 Mn
Sep 30, 2020 27.26 Mn
Jun 30, 2020 40.50 Mn
Mar 31, 2020 9.05 Mn